Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron’s CBO hops ship to lead startup – Endpoints News


→ Af­ter pass­ing their third straight Phase III tri­al for its new kind of di­a­betes tablet in Japan, French phar­ma Pox­el has tapped David Moller as CSO. Moller has fo­cused his ca­reer in the fields of di­a­betes and meta­bol­ic dis­or­ders. He most re­cent­ly served as CSO at Sig­ilon Ther­a­peu­tics and has pre­vi­ous­ly com­plet­ed stints at Eli Lil­ly, as VP of en­docrine and car­dio­vas­cu­lar re­search and clin­i­cal in­ves­ti­ga­tion, and Mer­ck, as VP of meta­bol­ic dis­or­ders. With his new role, Moller will be based in Boston.

→ Af­ter nab­bing an ok from the FDA for their be­ta-tha­lassemia drug Re­blozyl with their part­ner Cel­gene to treat ane­mia in adults who re­quire reg­u­lar trans­fu­sions, Ac­celeron‘s EVP and CBO John Quisel is hit­ting the ex­it. Quisel is head­ing to helm a ven­ture-backed start­up biotech com­pa­ny as CEO, though Ac­celeron isn’t say­ing which com­pa­ny that is. Quisel joined Ac­celeron in 2006.

Vivek Ra­maswamy‘s Roivant Sci­ences sub­sidiary Der­ma­vant has named Chris Chap­man as CCO. Chap­man joined the der­ma­tol­ogy-fo­cused com­pa­ny af­ter his re­cent stint as VP and gen­er­al man­ag­er, US pre­scrip­tion busi­ness for Gal­der­ma. Pri­or to his time at Gal­der­ma, Chap­man served in roles at Pfiz­er, Medicis Phar­ma­ceu­ti­cal and con­sult­ing firm The Core Ac­cess Group.

John Quisel - Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron’s CBO hops ship to lead startup – Endpoints NewsJohn Quisel Ac­celeron

→ San­thera Phar­ma­ceu­ti­cals — who, back in Au­gust, boast­ed pos­i­tive Phase IIa da­ta for their al­ter­na­tive steroid va­morolone — has brought on An­drew Smith as CFO. Most re­cent­ly, Smith served as the CFO and COO of Al­le­cra Ther­a­peu­tics. Pri­or to that, he did a stint as CFO at Su­cam­po Phar­ma­ceu­ti­cals.

→ CBD Em­po­ri­um — a re­tail­er of cannabid­i­ol prod­ucts — has snagged Paul Stein­berg as COO. Stein­berg’s pre­vi­ous stints in­clude roles at Abrax­is Bio­science (ac­quired by Cel­gene), PPD, Novel­la Clin­i­cal (a Quin­tiles com­pa­ny) and Sim­bec-Ori­on.

→ Sum­mit Ther­a­peu­tics — fo­cused on the de­vel­op­ment of an­tibi­otics — has an­nounced that its COO, CMO and pres­i­dent of R&D, David Rob­lin, is re­sign­ing. Rob­lin joined the com­pa­ny in ear­ly 2017.

→ Can­cer-fo­cused Avac­ta Group has wel­comed GSK vet Paul Fry as non-ex­ec­u­tive di­rec­tor. Fry hopped over to the com­pa­ny af­ter serv­ing as in­ter­im CEO at Vec­tura Group as well as CFO of the com­pa­ny. Pre­vi­ous­ly, Fry held roles at Im­muno­core and Voda­fone.

Percival Barretto Ko - Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron’s CBO hops ship to lead startup – Endpoints NewsPer­ci­val Bar­ret­to-Ko Astel­las

→ The for­mer pres­i­dent and COO of Sarep­ta Ther­a­peu­tics, Alan Tim­mins, has hopped aboard Cy­to­Dyn — cur­rent­ly de­vel­op­ing a CCR5 an­tag­o­nist, leron­limab (PRO 140) — as a mem­ber of the board of di­rec­tors as an in­de­pen­dent di­rec­tor and chair of the board’s au­dit com­mit­tee.

Be­yond­Spring, a can­cer-fo­cused biotech with deep roots in Chi­na, has brought on Roche vet Daniel Zabrows­ki and the com­pa­ny’s CMO and EVP, R&D Ra­mon Ma­han­lal to its board of di­rec­tors.

Astel­las Phar­ma’s US pres­i­dent Per­ci­val Bar­ret­to-Ko has joined the board of di­rec­tors, for a three-year long term, of health-fo­cused re­lief and de­vel­op­ment or­ga­ni­za­tion Ameri­cares.

Source link


Please enter your comment!
Please enter your name here